Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
July 23, 2026: Pharmacy Compounding Advisory Committee meeting The FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23, 2026 to evaluate BPC-157 and TB-500 (free base and acetate forms), along with KPV and MOTs-C
Any products and informational content displayed on this page are not intended to diagnose, treat, cure, or prevent any disease.
Lipid panel: clinical trials have documented triglyceride reductions on tesamorelin
Frequently Asked Questions What is BPC-157 studied for in research
This preparation is contraindicated in patients who are sensitive to cobalt and/or vitamin B12. As this product contains benzyl alcohol, it should not be used in newborns or in people who are sensitive to benzyl alcohol
However, BPC-157 may fall under WADAs broader categories prohibiting peptide hormones, growth factors, and related substances
US$ 20.58
US$ 26.25
US$ 23.70
US$ 29.63
US$ 26.38
US$ 23.88
US$ 26.00
